Entera Bio Ltd. Logo

Entera Bio Ltd.

Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.

ENTX | US

Overview

Corporate Details

ISIN(s):
IL0011429839
LEI:
Country:
United States of America
Address:
KIRYAT HADASSAH, MINRAV BUILDING, 9112002 JERUSALEM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development of orally delivered large molecule and peptide therapeutics. The company's proprietary N-Tab™ technology platform enables the oral administration of drugs that are typically injectable by stabilizing the active ingredients in the gastrointestinal tract and enhancing absorption. Entera's primary focus is on therapies for significant unmet medical needs. Its clinical pipeline is led by EB613, an oral parathyroid hormone (PTH) tablet for postmenopausal women with osteoporosis, and EB612 for patients with hypoparathyroidism. The company is also developing oral treatments for obesity and rare malabsorption conditions like short bowel syndrome.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Entera Bio Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Entera Bio Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Entera Bio Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Propanc Biopharma, Inc. Logo
Developing proenzyme therapies to prevent solid tumor recurrence and metastasis.
United States of America
PPCB
ProQR Therapeutics N.V. Logo
Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.
United States of America
PRQR
Protagenic Therapeutics, Inc.\new Logo
Developing novel peptide drugs to treat stress-related neuropsychiatric & CNS disorders.
United States of America
PTIX
Protagonist Therapeutics, Inc Logo
Develops peptide therapeutics for blood disorders and inflammatory or immunomodulatory diseases.
United States of America
PTGX
Protalix BioTherapeutics, Inc. Logo
Develops plant-cell-based protein therapies for rare diseases like Gaucher and Fabry.
United States of America
PLX
Protara Therapeutics, Inc. Logo
Clinical-stage biotech developing cell therapies for cancer and rare diseases.
United States of America
TARA
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea
468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea
303360
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom
PSY
PSYENCE BIOMEDICAL LTD. Logo
Developing natural psilocybin therapies for anxiety and depression in palliative care.
United States of America
PBM

Talk to a Data Expert

Have a question? We'll get back to you promptly.